Nrf2 Signaling Pathway in Chemoprotection and Doxorubicin Resistance: Potential Application in Drug Discovery

Nrf2 Signaling Pathway in Chemoprotection and Doxorubicin Resistance: Potential Application in Drug Discovery

Doxorubicin (DOX) is extensively applied in cancer therapy due to its efficacy in suppressing cancer progression and inducing apoptosis. After its discovery, this chemotherapeutic agent has been frequently used for cancer therapy, leading to chemoresistance. Due to dose-dependent toxicity, high conc...

Full description

Bibliographic Details
Main Authors: Sepideh Mirzaei, Ali Zarrabi, Farid Hashemi, Amirhossein Zabolian, Hossein Saleki, Negar Azami, Soodeh Hamzehlou, Mahdi Vasheghani Farahani, Kiavash Hushmandi, Milad Ashrafizadeh, Haroon Khan, Alan Prem Kumar
Format: Article
Language:English
Published: MDPI AG 2021-02-01
Series:Antioxidants
Subjects:
doxorubicin
chemoresistance
oxidative stress
redox signaling
nuclear factor erythroid 2-related factor 2 (Nrf2), cancer therapy
Online Access:https://www.mdpi.com/2076-3921/10/3/349

Internet

https://www.mdpi.com/2076-3921/10/3/349

Similar Items